Health Catalyst (HCAT)
(Delayed Data from NSDQ)
$7.70 USD
-0.07 (-0.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $7.64 -0.06 (-0.78%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
HCAT 7.70 -0.07(-0.90%)
Will HCAT be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for HCAT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HCAT
Health Catalyst (HCAT) Upgraded to Buy: Here's What You Should Know
Health Catalyst (HCAT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
HCAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates
Time to Play 5 Top-Ranked Stocks With Rising P/E?
Do Options Traders Know Something About Health Catalyst (HCAT) Stock We Don't?
Other News for HCAT
Insider Sale: Chief People Officer Linda Llewelyn Sells Shares of Health Catalyst Inc (HCAT)
Health Catalyst price target raised by $2 at Evercore ISI, here's why
What Analysts Are Saying About Health Catalyst Stock
Notable Two Hundred Day Moving Average Cross - HCAT
Health Catalyst: Still Optimistic On Achieving Adjusted EBITDA Targets